Heart drug for kids under safety watch

NCT ID NCT06659393

Summary

This study aims to monitor the safety of the heart medication Entresto in children aged 1 to 18 with chronic heart failure. It will follow 33 children in Japan for up to one year after they start taking the drug in their regular doctor's care. The main goal is to check for side effects like low blood pressure, high potassium, and kidney problems.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Ōbu, Aichi-ken, 474 8710, Japan

  • Novartis Investigative Site

    RECRUITING

    Toyoake, Aichi-ken, 470 1192, Japan

  • Novartis Investigative Site

    RECRUITING

    Fukuoka, Fukuoka, 812-8582, Japan

  • Novartis Investigative Site

    RECRUITING

    Kurume, Fukuoka, 830-0011, Japan

  • Novartis Investigative Site

    RECRUITING

    Kurume, Fukuoka, 830-8543, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 060 8648, Japan

  • Novartis Investigative Site

    RECRUITING

    Tsukuba, Ibaraki, 305-8576, Japan

  • Novartis Investigative Site

    RECRUITING

    Kawasaki, Kanagawa, 216-8511, Japan

  • Novartis Investigative Site

    RECRUITING

    Yokohama, Kanagawa, 236-0004, Japan

  • Novartis Investigative Site

    RECRUITING

    Tsu, Mie-ken, 514-8507, Japan

  • Novartis Investigative Site

    RECRUITING

    Nagasaki, Nagasaki, 852-8501, Japan

  • Novartis Investigative Site

    RECRUITING

    Ōmura, Nagasaki, 856-8562, Japan

  • Novartis Investigative Site

    RECRUITING

    Okayama, Okayama-ken, 700-8558, Japan

  • Novartis Investigative Site

    RECRUITING

    Hidaka, Saitama, 350-1298, Japan

  • Novartis Investigative Site

    RECRUITING

    Saitama, Saitama, 330 8777, Japan

  • Novartis Investigative Site

    RECRUITING

    Hamamatsu, Shizuoka, 430-8558, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 113 8655, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 113-8431, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • Novartis Investigative Site

    RECRUITING

    Fuchū, Tokyo, 183-0003, Japan

  • Novartis Investigative Site

    RECRUITING

    Fuchū, Tokyo, 183-8561, Japan

  • Novartis Investigative Site

    RECRUITING

    Ōta-ku, Tokyo, 143 8541, Japan

  • Novartis Investigative Site

    RECRUITING

    Setagaya-ku, Tokyo, 157-8535, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinagawa-ku, Tokyo, 142-8666, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinjuku Ku, Tokyo, 162 8666, Japan

  • Novartis Investigative Site

    RECRUITING

    Toyama, Toyama, 930-0194, Japan

  • Novartis Investigative Site

    RECRUITING

    Akita, 010-8543, Japan

  • Novartis Investigative Site

    RECRUITING

    Kumamoto, 862-8505, Japan

Conditions

Explore the condition pages connected to this study.